Weixian Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weixian Yang has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Lin Zhao
Department of Integrative Medicine Cardiology, China-Japan Friendship Hospital, Beijing, China
6 shared publicationsLin Sun
Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 shared publicationsMan Wang
Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 shared publicationsTianjie Wang
Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4 shared publicationsKunQi Yang
Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 shared publications- Xian-Liang Zhou
Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 shared publications
Latest Publications
- 29 January 2026
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 107 (8) , 2219-2226
Current Status of Cardiac Rehabilitation in China: A Cross-sectional National Survey
- 29 January 2026
- Published by Elsevier in Archives of Physical Medicine and Rehabilitation
- Vol. 107 (8) , 2219-2226
Current Status of Cardiac Rehabilitation in China: A Cross-sectional National Survey
- Open Access
Anti-inflammatory therapy for recurrent in-stent restenosis (AI-ISR): study protocol for a prospective, randomised, open-label, multicentre clinical trial
Introduction Recurrent in-stent restenosis (RISR) remains a major therapeutic challenge in patients undergoing percutaneous coronary intervention (PCI), with a high incidence of repeat revascularisation and increased mortality. Immune-mediated inflammation has been implicated in the pathogenesis of RISR. This trial aims to evaluate the clinical efficacy and safety of two anti-inflammatory strategies—low-dose colchicine and prednisone—on reducing ISR recurrence and cardiovascular events. Methods and analysis This is a multicentre, prospective, randomised, open-label controlled trial enrolling 252 patients with RISR. Following successful PCI, patients are randomly assigned (1:1:1) to receive: (1) standard medical therapy (control group); (2) colchicine 0.5 mg/day (colchicine group) or (3) prednisone 0.5 mg/kg/day, tapered monthly to 5–10 mg/day over 12 months (prednisone group). All groups receive background standard therapy per guidelines. The primary endpoint is angiographically confirmed ISR of the target lesion at 12 months post PCI. Secondary endpoints include the incidence of major adverse cardiovascular and cerebrovascular events (cardiovascular death, myocardial infarction, stroke and target vessel revascularisation), target lesion revascularisation and revascularisation of non-target coronary lesions within 12 months. Ethics and dissemination This trial has received ethical approval from the Ethics Committee of Fuwai Hospital (Chinese Academy of Medical Sciences and Peking Union Medical College), which acts as the central institutional review board. All participants will provide written informed consent. Study results will be disseminated via peer-reviewed journals and conference presentations. Trial registration number ClinicalTrials.gov, NCT06090890. Registered 15 October 2023, https://clinicaltrials.gov/study/NCT06090890.
Open AccessAnti-inflammatory therapy for recurrent in-stent restenosis (AI-ISR): study protocol for a prospective, randomised, open-label, multicentre clinical trial
Introduction Recurrent in-stent restenosis (RISR) remains a major therapeutic challenge in patients undergoing percutaneous coronary intervention (PCI), with a high incidence of repeat revascularisation and increased mortality. Immune-mediated inflammation has been implicated in the pathogenesis of RISR. This trial aims to evaluate the clinical efficacy and safety of two anti-inflammatory strategies—low-dose colchicine and prednisone—on reducing ISR recurrence and cardiovascular events. Methods and analysis This is a multicentre, prospective, randomised, open-label controlled trial enrolling 252 patients with RISR. Following successful PCI, patients are randomly assigned (1:1:1) to receive: (1) standard medical therapy (control group); (2) colchicine 0.5 mg/day (colchicine group) or (3) prednisone 0.5 mg/kg/day, tapered monthly to 5–10 mg/day over 12 months (prednisone group). All groups receive background standard therapy per guidelines. The primary endpoint is angiographically confirmed ISR of the target lesion at 12 months post PCI. Secondary endpoints include the incidence of major adverse cardiovascular and cerebrovascular events (cardiovascular death, myocardial infarction, stroke and target vessel revascularisation), target lesion revascularisation and revascularisation of non-target coronary lesions within 12 months. Ethics and dissemination This trial has received ethical approval from the Ethics Committee of Fuwai Hospital (Chinese Academy of Medical Sciences and Peking Union Medical College), which acts as the central institutional review board. All participants will provide written informed consent. Study results will be disseminated via peer-reviewed journals and conference presentations. Trial registration number ClinicalTrials.gov, NCT06090890. Registered 15 October 2023, https://clinicaltrials.gov/study/NCT06090890.
- Open Access
- 14 July 2025
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 25 (1) , 1-9
Diabetes is associated with a poor prognosis in patients with psoriasis and coronary artery disease
Background: There is an increased risk of diabetes and cardiovascular disease among patients with psoriasis. However, whether diabetes affects the cardiovascular adverse events in patients with psoriasis who have suffered from coronary artery disease remains unclear. This study aimed to explore the prognostic role of diabetes in this particular population. Methods: This single-center, retrospective cohort study included all consecutive adult patients with psoriasis and coronary artery disease admitted at our hospital between January 2017 and May 2022. Clinical records were collected and compared between patients with and without diabetes. Survival curves were derived using Kaplan–Meier methods. Multivariable Cox regression was used to control potential confounding. Results: This study included 305 participants, including 147 patients (48.2%) with diabetes. Patients with diabetes were more likely to have hypertension (p = 0.045), peripheral vascular disease (p = 0.043) and the history of stroke (p = 0.041). Patients with diabetes also had higher levels of low-density lipoprotein cholesterol (p = 0.039) and homocysteine (p = 0.006). After a median follow-up of 36 months, patients with diabetes had a higher incidence of major adverse cardiovascular events (MACE) than patients without diabetes (p = 0.032). According to the results of the Cox regression analysis, only diabetes (p = 0.039) was associated with MACE. The subgroup analysis showed that diabetes was associated with MACE, especially in male patients (p = 0.008) and those without chronic kidney disease (p = 0.021). Conclusion: In patients with psoriasis and coronary artery disease, diabetes is independently linked with MACE. These findings will help the risk assessment for patients with psoriasis and coronary artery disease.
- 14 July 2025
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 25 (1) , 1-9
Open AccessDiabetes is associated with a poor prognosis in patients with psoriasis and coronary artery disease
Background: There is an increased risk of diabetes and cardiovascular disease among patients with psoriasis. However, whether diabetes affects the cardiovascular adverse events in patients with psoriasis who have suffered from coronary artery disease remains unclear. This study aimed to explore the prognostic role of diabetes in this particular population. Methods: This single-center, retrospective cohort study included all consecutive adult patients with psoriasis and coronary artery disease admitted at our hospital between January 2017 and May 2022. Clinical records were collected and compared between patients with and without diabetes. Survival curves were derived using Kaplan–Meier methods. Multivariable Cox regression was used to control potential confounding. Results: This study included 305 participants, including 147 patients (48.2%) with diabetes. Patients with diabetes were more likely to have hypertension (p = 0.045), peripheral vascular disease (p = 0.043) and the history of stroke (p = 0.041). Patients with diabetes also had higher levels of low-density lipoprotein cholesterol (p = 0.039) and homocysteine (p = 0.006). After a median follow-up of 36 months, patients with diabetes had a higher incidence of major adverse cardiovascular events (MACE) than patients without diabetes (p = 0.032). According to the results of the Cox regression analysis, only diabetes (p = 0.039) was associated with MACE. The subgroup analysis showed that diabetes was associated with MACE, especially in male patients (p = 0.008) and those without chronic kidney disease (p = 0.021). Conclusion: In patients with psoriasis and coronary artery disease, diabetes is independently linked with MACE. These findings will help the risk assessment for patients with psoriasis and coronary artery disease.
- Open Access
- 31 July 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-12
The triglyceride-glucose index is a predictor of major adverse cardiovascular events in patients with coronary artery disease and psoriasis: a retrospective cohort study
Background: The association between the triglyceride-glucose (TyG) index and clinical outcomes in patients with both coronary artery disease (CAD) and psoriasis is unclear. This study investigated the association between the TyG index and major adverse cardiovascular events (MACE) in patients with both CAD and psoriasis. Methods: This retrospective cohort study included patients diagnosed with both CAD and psoriasis who underwent coronary angiography at the Fuwai Hospital, Beijing, China, between January 2017 and May 2022. The study endpoint was the occurrence of MACE or end of follow-up time. Multivariate Cox proportional analysis and restricted cubic splines (RCS) were used to determine the association between the TyG index and MACE. Receiver operating characteristic (ROC) curves were used to determine the optimal threshold value of the TyG index for predicting MACE. Results: This study enrolled 293 patients with both CAD and psoriasis, including 258 (88.1%) males with a mean age of 58.89 ± 9.61 years. Patients were divided into four groups based on the TyG quartiles: Q1 (N = 74), Q2 (N = 73), Q3 (N = 73), and Q4 (N = 73). After adjusting for the potential confounders, the TyG index was independently associated with MACE, both as a continuous variable (HR = 1.53, 95% CI = 1.03–2.28, P = 0.035) and as a categorical variable (Q1: reference; Q2: HR = 1.85, 95% CI = 0.88–3.87, P = 0.105; Q3: HR = 2.39, 95% CI = 1.14-5.00, P = 0.021; Q4: HR = 2.19, 95% CI = 1.001–4.81, P = 0.0497; P for trend = 0.039). RCS analysis showed an linear association between the TyG index and MACE (P-overall = 0.027, P-non-linear = 0.589). ROC curve analysis showed that the TyG index of ≥ 8.73 was the optimal threshold value (area under the ROC curve = 0.60, 95% CI 0.53–0.67). TyG index ≥ 8.73 was significantly associated with MACE (HR = 2.10, 95% CI = 1.32–3.34, P = 0.002). After adjustment for confounders, the TyG index showed independent association with MACE (HR = 2.00, 95% CI = 1.17–3.42, P = 0.011). Conclusions: The TyG index showed a positive linear correlation with MACE in patients with both CAD and psoriasis. The TyG index of ≥ 8.73 might be the optimal threshold for predicting MACE. Graphical
- 31 July 2024
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-12
Open AccessThe triglyceride-glucose index is a predictor of major adverse cardiovascular events in patients with coronary artery disease and psoriasis: a retrospective cohort study
Background: The association between the triglyceride-glucose (TyG) index and clinical outcomes in patients with both coronary artery disease (CAD) and psoriasis is unclear. This study investigated the association between the TyG index and major adverse cardiovascular events (MACE) in patients with both CAD and psoriasis. Methods: This retrospective cohort study included patients diagnosed with both CAD and psoriasis who underwent coronary angiography at the Fuwai Hospital, Beijing, China, between January 2017 and May 2022. The study endpoint was the occurrence of MACE or end of follow-up time. Multivariate Cox proportional analysis and restricted cubic splines (RCS) were used to determine the association between the TyG index and MACE. Receiver operating characteristic (ROC) curves were used to determine the optimal threshold value of the TyG index for predicting MACE. Results: This study enrolled 293 patients with both CAD and psoriasis, including 258 (88.1%) males with a mean age of 58.89 ± 9.61 years. Patients were divided into four groups based on the TyG quartiles: Q1 (N = 74), Q2 (N = 73), Q3 (N = 73), and Q4 (N = 73). After adjusting for the potential confounders, the TyG index was independently associated with MACE, both as a continuous variable (HR = 1.53, 95% CI = 1.03–2.28, P = 0.035) and as a categorical variable (Q1: reference; Q2: HR = 1.85, 95% CI = 0.88–3.87, P = 0.105; Q3: HR = 2.39, 95% CI = 1.14-5.00, P = 0.021; Q4: HR = 2.19, 95% CI = 1.001–4.81, P = 0.0497; P for trend = 0.039). RCS analysis showed an linear association between the TyG index and MACE (P-overall = 0.027, P-non-linear = 0.589). ROC curve analysis showed that the TyG index of ≥ 8.73 was the optimal threshold value (area under the ROC curve = 0.60, 95% CI 0.53–0.67). TyG index ≥ 8.73 was significantly associated with MACE (HR = 2.10, 95% CI = 1.32–3.34, P = 0.002). After adjustment for confounders, the TyG index showed independent association with MACE (HR = 2.00, 95% CI = 1.17–3.42, P = 0.011). Conclusions: The TyG index showed a positive linear correlation with MACE in patients with both CAD and psoriasis. The TyG index of ≥ 8.73 might be the optimal threshold for predicting MACE. Graphical
- Open Access
- 27 March 2024
- Published by Elsevier in International Journal of Cardiology Cardiovascular Risk and Prevention
- Vol. 21, 200265
Development and validation of a risk score nomogram model to predict the risk of 5-year all-cause mortality in diabetic patients with hypertension: A study based on NHANES data
- 27 March 2024
- Published by Elsevier in International Journal of Cardiology Cardiovascular Risk and Prevention
- Vol. 21, 200265
Open AccessDevelopment and validation of a risk score nomogram model to predict the risk of 5-year all-cause mortality in diabetic patients with hypertension: A study based on NHANES data
- Open Access
- 2 September 2023
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 22 (1) , 1-12
Lipoprotein(a) is a new prognostic factor in patients with psoriasis and coronary artery disease: a retrospective cohort study
Background: The prognostic value of lipoprotein (Lp) (a) in patients who have suffered from coronary artery disease (CAD) has not been fully studied, and the results are inconsistent. This study was conducted to evaluate whether increased Lp(a) concentrations cause differences in clinical adverse outcomes in patients with psoriasis who have already suffered from CAD. Methods: This retrospective cohort study included consecutive patients with psoriasis and CAD between January 2017 and May 2022 in our hospital. The clinical records were collected, and comparisons were made between patients in the low Lp(a) and high Lp(a) groups. Cox proportional hazard analysis and log-rank tests were used to evaluate the association between variables. Results: Among 295 patients, 148 patients were in the low Lp(a) group, and 147 were in the high Lp(a) group. These two groups did not differ significantly in age, gender or body mass index. Compared with the low Lp(a) group, the levels of platelet counts (P = 0.038) and high sensitivity C reactive protein (P = 0.012) were higher in the high Lp(a) group. Patients in the high Lp(a) group had higher total cholesterol levels (P = 0.029) and lower triglyceride levels (P = 0.037). Among the whole cohort, clinical adverse events were not correlated with Lp(a) concentrations after a median follow-up of 3 years. However, in the subgroup analysis, there were significant differences in all-cause death (log rank P = 0.036) and rehospitalization (log rank P = 0.037) between the two groups in patients with diabetes; a difference in rehospitalization (log rank P = 0.042) was also found between the two groups in men. Conclusions: In patients with psoriasis and CAD, high levels of Lp(a) were related to a poor prognosis, especially in patients with diabetes and in men. These results will provide valuable information for the risk stratification of patients with psoriasis and CAD.
- 2 September 2023
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 22 (1) , 1-12
Open AccessLipoprotein(a) is a new prognostic factor in patients with psoriasis and coronary artery disease: a retrospective cohort study
Background: The prognostic value of lipoprotein (Lp) (a) in patients who have suffered from coronary artery disease (CAD) has not been fully studied, and the results are inconsistent. This study was conducted to evaluate whether increased Lp(a) concentrations cause differences in clinical adverse outcomes in patients with psoriasis who have already suffered from CAD. Methods: This retrospective cohort study included consecutive patients with psoriasis and CAD between January 2017 and May 2022 in our hospital. The clinical records were collected, and comparisons were made between patients in the low Lp(a) and high Lp(a) groups. Cox proportional hazard analysis and log-rank tests were used to evaluate the association between variables. Results: Among 295 patients, 148 patients were in the low Lp(a) group, and 147 were in the high Lp(a) group. These two groups did not differ significantly in age, gender or body mass index. Compared with the low Lp(a) group, the levels of platelet counts (P = 0.038) and high sensitivity C reactive protein (P = 0.012) were higher in the high Lp(a) group. Patients in the high Lp(a) group had higher total cholesterol levels (P = 0.029) and lower triglyceride levels (P = 0.037). Among the whole cohort, clinical adverse events were not correlated with Lp(a) concentrations after a median follow-up of 3 years. However, in the subgroup analysis, there were significant differences in all-cause death (log rank P = 0.036) and rehospitalization (log rank P = 0.037) between the two groups in patients with diabetes; a difference in rehospitalization (log rank P = 0.042) was also found between the two groups in men. Conclusions: In patients with psoriasis and CAD, high levels of Lp(a) were related to a poor prognosis, especially in patients with diabetes and in men. These results will provide valuable information for the risk stratification of patients with psoriasis and CAD.
- Open Access
- 1 September 2023
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 16, 4019-4030
Fibrinogen is Associated with Clinical Adverse Events in Patients with Psoriasis and Coronary Artery Disease
Purpose: The presence of elevated fibrinogen levels is associated with cardiovascular disease. However, whether fibrinogen level is associated with adverse clinical events in patients with psoriasis and coronary artery disease (CAD) is unknown. This study aimed to investigate the relationship between fibrinogen levels and cardiovascular adverse events in these patients. Patients and Methods: This retrospective cohort study collected consecutive patients with psoriasis and CAD between January 2017 and May 2022 in our hospital. The clinical records were collected, and comparisons were made between groups. The Cox regression analysis and Kaplan–Meier survival analysis were used to evaluate the association between variables. Results: Of the 267 participants, one hundred and forty-seven patients (55.1%) had elevated fibrinogen levels. Compared with patients in low fibrinogen group, white blood cell and platelet counts and high-sensitivity C-reactive protein levels were higher, whereas the left ventricular ejection fraction was lower in patients in high fibrinogen group. After a median follow-up of 35.5 months, the incidence of major adverse cardiovascular events (MACEs) was higher in patients in high fibrinogen group compared with patients in low fibrinogen group (31.4% vs 16.4%, p = 0.013). The Kaplan–Meier survival curves showed the same trend (log rank p = 0.020). Subgroup analysis revealed a positive association between elevated fibrinogen levels and MACEs in patients aged < 60 years (log-rank p = 0.013), those with diabetes (log-rank p = 0.027), and those who were not admitted for acute cardiovascular syndrome (log-rank p = 0.015). Conclusion: Elevated fibrinogen levels were associated with adverse clinical events in patients with psoriasis and CAD, especially among patients aged < 60 years, those with diabetes, and those not admitted for acute cardiovascular syndrome.
- 1 September 2023
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 16, 4019-4030
Open AccessFibrinogen is Associated with Clinical Adverse Events in Patients with Psoriasis and Coronary Artery Disease
Purpose: The presence of elevated fibrinogen levels is associated with cardiovascular disease. However, whether fibrinogen level is associated with adverse clinical events in patients with psoriasis and coronary artery disease (CAD) is unknown. This study aimed to investigate the relationship between fibrinogen levels and cardiovascular adverse events in these patients. Patients and Methods: This retrospective cohort study collected consecutive patients with psoriasis and CAD between January 2017 and May 2022 in our hospital. The clinical records were collected, and comparisons were made between groups. The Cox regression analysis and Kaplan–Meier survival analysis were used to evaluate the association between variables. Results: Of the 267 participants, one hundred and forty-seven patients (55.1%) had elevated fibrinogen levels. Compared with patients in low fibrinogen group, white blood cell and platelet counts and high-sensitivity C-reactive protein levels were higher, whereas the left ventricular ejection fraction was lower in patients in high fibrinogen group. After a median follow-up of 35.5 months, the incidence of major adverse cardiovascular events (MACEs) was higher in patients in high fibrinogen group compared with patients in low fibrinogen group (31.4% vs 16.4%, p = 0.013). The Kaplan–Meier survival curves showed the same trend (log rank p = 0.020). Subgroup analysis revealed a positive association between elevated fibrinogen levels and MACEs in patients aged < 60 years (log-rank p = 0.013), those with diabetes (log-rank p = 0.027), and those who were not admitted for acute cardiovascular syndrome (log-rank p = 0.015). Conclusion: Elevated fibrinogen levels were associated with adverse clinical events in patients with psoriasis and CAD, especially among patients aged < 60 years, those with diabetes, and those not admitted for acute cardiovascular syndrome.
- Open Access
- 27 July 2023
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (6) , 1303-1313
Preliminary Study on Retrograde Recanalization of Radial Artery Occlusion Through Distal Radial Artery Access: a Single-Center Experience
Purpose: Radial artery occlusion (RAO) is an unresolved complication after transradial artery (TRA) puncture. The aim of this observational study was to assess the feasibility and safety of retrograde recanalization of RAO through distal transradial access (dTRA). Methods: From June 2021 to March 2022, 28 consecutive patients with successful puncture and intubation through the dTRA in the anatomical snuffbox and RAO confirmed by angiography were enrolled. Results: Among the 28 patients, 27 (96.4%) patients with RAO were successfully retrogradely recanalized through the dTRA and successfully underwent coronary angiography or coronary intervention. After the procedure, only 1 (3.7%) patient developed a forearm hematoma, and there were no other bleeding complications or nerve disorders. Conclusions: DTRA is a safe and feasible approach for retrograded recanalization of RAO, with a high procedure success rate and few complications.
- 27 July 2023
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (6) , 1303-1313
Open AccessPreliminary Study on Retrograde Recanalization of Radial Artery Occlusion Through Distal Radial Artery Access: a Single-Center Experience
Purpose: Radial artery occlusion (RAO) is an unresolved complication after transradial artery (TRA) puncture. The aim of this observational study was to assess the feasibility and safety of retrograde recanalization of RAO through distal transradial access (dTRA). Methods: From June 2021 to March 2022, 28 consecutive patients with successful puncture and intubation through the dTRA in the anatomical snuffbox and RAO confirmed by angiography were enrolled. Results: Among the 28 patients, 27 (96.4%) patients with RAO were successfully retrogradely recanalized through the dTRA and successfully underwent coronary angiography or coronary intervention. After the procedure, only 1 (3.7%) patient developed a forearm hematoma, and there were no other bleeding complications or nerve disorders. Conclusions: DTRA is a safe and feasible approach for retrograded recanalization of RAO, with a high procedure success rate and few complications.
- Open Access
Serum total bilirubin and one-year prognosis of patients with coronary artery disease and psoriasis